StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)

Close on Nov 13, 2026Market cap $1.69BP/E –Yield –

Vir Biotechnology gross margin

Gross margin is gross profit as a percentage of revenue.

Vir Biotechnology's gross margin for the twelve months ending Jun 30, 2025 was 96.1%. For fiscal 2025 it was 100.0%, against 98.9% the year before. The highest annual figure on record is 100.0% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025100.0%+1.1
FY2024Dec 31, 202498.9%+2.1
FY2023Dec 31, 202396.8%+5.8
FY2022Dec 31, 202290.9%−3.0
FY2021Dec 31, 202194.0%−6.0
FY2020Dec 31, 2020100.0%+0.0
FY2019Dec 31, 2019100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026100.0%+2.1
Q2 FY2025Jun 30, 202599.1%+0.8
Q1 FY2025Mar 31, 2025100.0%+0.1
Q4 FY2024Dec 31, 202494.5%−0.8
Q3 FY2024Sep 30, 202497.9%−0.7
Q2 FY2024Jun 30, 202498.3%−1.1
Q1 FY2024Mar 31, 202499.9%+2.9
Q4 FY2023Dec 31, 202395.2%+7.4
Q3 FY2023Sep 30, 202398.6%+4.5
Q2 FY2023Jun 30, 202399.4%+6.7
Q1 FY2023Mar 31, 202397.0%+4.0
Q4 FY2022Dec 31, 202287.9%−4.6
Q3 FY2022Sep 30, 202294.1%−5.3
Q1 FY2022Mar 31, 202292.7%−7.3
Q4 FY2021Dec 31, 202193.0%−7.0
Q3 FY2021Sep 30, 202192.4%−7.6
Q2 FY2021Jun 30, 202199.4%−0.6
Q1 FY2021Mar 31, 2021100.0%–
Q4 FY2020Dec 31, 2020100.0%–
Q3 FY2020Sep 30, 2020100.0%–
Q2 FY2020Jun 30, 2020100.0%–

More Vir Biotechnology figures

See a number that looks wrong?